02.03.01. Investigación y comunicación científica

Scar with aneurysm and thrombus in the hyperacute phase after ventricular tachycardia ablation

2026-04-20T09:52:42Z

Scar with aneurysm and thrombus in the hyperacute phase after ventricular tachycardia ablation Merelo-Nicolás, Marta; Castro-Arias, Roberto; Egea-Serrano, Pilar

Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort

2026-04-20T09:52:40Z

Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort Llorca, Javier; Ferraz-Amaro, Iván; Moreno-Martínez, María-José; Plaza, Zulema; Sánchez-Alonso, Fernando; Moreno-Ramos, Manuel-José; García-Gómez, Carmen; Castaneda, Santos; González-Juanatey, Carlos; González-Gay, Miguel-Ángel Objective: To identify predictors of cardiovascular (CV) events in psoriatic arthritis (PsA) patients from the CARdiovascular in RheuMAtology (CARMA) project during 10 years of prospective follow-up. Methods: Between July 2010 and January 2012, 725 PsA patients were enrolled from 67 Spanish hospitals. Analyses focused on 682 patients without prior CV events at baseline. At 10-year follow-up, CV event occurrence, patient-years, and linearized event rates were evaluated. Cox regression analyses were performed, both crude and adjusted for the PREVENT-CVD score. Results: Over 6397 patient-years, 85 patients (12.46%) experienced CV events, yielding a rate of 1.33 per 100 patient-years. Patients with CV events were older (67.1 +/- 11.1 vs. 56.7 +/- 11.8 years, p < 0.001), more often male (68.2% vs. 51.9%, p = 0.005), and had higher frequencies of hypertension (60.0% vs. 21.8%, p < 0.001), diabetes (18.8% vs. 6.0%, p = 0.001), and dyslipidemia (56.5% vs. 29.8%, p < 0.001). They also showed greater abdominal perimeter and body mass index (p < 0.05 for both). After adjusting for PREVENT-CVD, the highest tertile of DAS28-ESR remained a significant predictor of CV events (HR 1.79; 95%CI: 1.03-3.14; p = 0.04). Urate in the highest tertile was also independently associated in the crude model (HR 1.88; 95%CI: 1.11-3.20; p = 0.02). When stratified (<6.5, 6.5-8.9, and >= 9.0 mg/dl), urate >= 9.0 mg/dl was also associated with increased risk of CV events in the adjusted model (HR 3.50; 95%CI: 1.10-11.2; p = 0.02). While HAQ score in the third tertile was associated with increased CV risk in the crude analysis (HR 1.70; p = 0.04), this association did not persist after adjustment. Conclusions: Disease activity and elevated urate levels independently predict CV events in PsA, highlighting their value as markers of CV risk beyond traditional factors captured by the PREVENT-CVD score.

Prescribing medicines in primary care teams: the challenge of multidisciplinarity and patient safety

2026-04-20T09:52:38Z

Prescribing medicines in primary care teams: the challenge of multidisciplinarity and patient safety Luzón-Oliver, Lourdes; Astier-Peña, María-Pilar

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review

2026-04-06T11:22:53Z

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review Calvo-Río, Vanesa; Secada-Gómez, Carmen; Martín-Gutierrez, Adrián; Retuerto-Guerrero, Miriam; Font, Judit; Casafont-Sole, Ivette; Mayo-Juanatey, Adrián; Alegre-Sancho, Juan-José; Freites, Dalifer; Hormigos, Cristina; Garrido-Puñal, Noemi; González-Arribas, Guillermo; Miguélez-Sánchez, Juan-Roberto; García-Valle, Andrea; Ibáñez, Marta; Lozano-Morillo, Fernando; García-Manzanares, Ángel; Sandoval-Moreno, Sebastián; Cortés-Hernández, Josefina; Palma-Sánchez, Deseada; Lojo, Leticia; Cervantes-Pérez, Evelin-Cecilia; Collado, Paz; Arciniega-Larios, Cristina; Sala-Icardo, Luis; Labrador-Sánchez, Eztizen; Peralta-Gines, Cilia; Urionaguena-Onaindia, Irati; Plaza-Aulestia, Nahia; Medina-Malone, Miguel; Rosas-Gómez-de-Salazar, José; Corteguera, Montserrat; Cebrian-Mendez, Laura; Anton-Pages, Fred-Antonio; Lamua-Riazuelo, José-Ramón; Fábregas-Canales, María-Dolores; Alados-Hernández, María-José; Garijo-Bufort, Marta; Pamies, Anna; Sarabia-De-Ardanaz, Luis; Aguirre-del-Pino, Rodrigo; Cabezas-Lefler, José-Ángel; Seijas-López, Alvaro; Carrasco-Cubero, María-del-Carmen; López-Ceron-Cofino, Ana; Ortiz-Santamaria, Vera; Laino-Pineiro, María; Ordas-Calvo, Carmen; Arconada-López, Celia; Urruticoechea-Arana, Ana; García-Magallon, Blanca; Acosta-Alfaro, Ana-Valeria; Leal-Rodríguez, Samuel; Salido-Olivares, Marina; Lavilla-Villar, Patricia; Brandy-García, Anahy-M; Ros-Vilamajo, Inmaculada; García-Martos, Álvaro; Magallares-López, Berta-Paula; Sada-Urmeneta, Guillen; Córdoba-Martin, Cristina; Riera, Elena; Bejerano, Carmen; Castañeeda, Santos; Blanco, Ricardo BACKGROUND: Anifrolumab is approved for adults with moderate-to-severe active systemic lupus erythematosus (SLE) based on Randomised clinical trials (RCTs). While randomised pivotal RCTs have demonstrated their efficacy and safety, real-world evidence (RWE) remains limited. OBJECTIVES: To describe the clinical characteristics, effectiveness and safety of anifrolumab in clinical practice and to assess findings from published observational studies. METHODS: Multicentre study of patients with SLE classified according to EULAR/American College of Rheumatology (ACR) 2019. Data were collected from medical records up to 30 April 2025. Variables included demographic characteristics, clinical and serological features, prior and concomitant therapies, disease activity indices including the SLE Disease Activity Index 2000 (SLEDAI-2K), SLE Disease Activity Score (SLE-DAS) and Physician Global Assessment (PGA), damage and disease control measures including the Systemic Lupus International Collaborating Clinics/ACR Damage Index, Lupus Low Disease Activity State (LLDAS) and Definitions of Remission in SLE (DORIS) remission and the association with adverse events (AEs). A review of published observational studies was also conducted. RESULTS: We included 206 patients (183 women; mean age 44.6±12.6 years) from 54 Spanish centres. The most common indications for anifrolumab were cutaneous (61.7%), musculoskeletal (48.5%) and haematological (27.2%).A rapid and sustained improvement was observed in disease activity (SLEDAI-2K, SLE-DAS, PGA), LLDAS, DORIS remission, serological markers (anti-double-stranded DNA, C3/C4) and corticosteroid tapering. Organ damage remained stable. After a mean follow-up of 7.5±5.3 months, the most frequent AEs were herpes zoster (n=?5), respiratory infections (n=?6) and headache (n=?3). Twenty patients discontinued treatment. These results were consistent with published observational studies. CONCLUSION: In this large RWE cohort, anifrolumab demonstrated early and sustained clinical benefit, a favourable safety profile and a significant corticosteroid-sparing effect. These findings reinforce the evidence from CT and support the incorporation of anifrolumab into routine care for patients with SLE.